The supplemental New Drug Application (sNDA) was supported by results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adult...
CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia...
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements ...
Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background Administered...
CSL and Alentis Therapeutics announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which ha...
AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBM...
Johnson & Johnson, a worldwide leader in multiple myeloma, announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and...
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Company has entered ...
Silo Pharma (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug del...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion r...
Eisai Co., Ltd. and Biogen Inc. announced that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (su...
Telix Pharmaceuticals Limited announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET imaging agent...
Eisai Co., Ltd. and Biogen Inc., announced that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of...
- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of p...
© 2026 Biopharma Boardroom. All Rights Reserved.
